Cellectar Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Cellectar Biosciences sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 5 completed early-phase tilt top decile by trial count

Cellectar Biosciences: 10 sponsored US clinical trials, 1 recruiting.

Cellectar Biosciences sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pediatric Lymphoma, with 1 trials.

Top-decile sponsor footprint

Cellectar Biosciences ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 1

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

NCT07311993
ACTIVE NOT RECRUITING Phase 1

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

NCT05610891
ACTIVE NOT RECRUITING Phase 1

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

NCT03478462
ACTIVE NOT RECRUITING Phase 2

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508
COMPLETED Phase 1

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

NCT02278315
TERMINATED Phase 2

Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma

NCT01898273
COMPLETED Phase 1

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

NCT01495663
COMPLETED Phase 2

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

NCT01058512
COMPLETED Phase 3

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

NCT00347412
COMPLETED Phase 2

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

NCT00345540

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 4
Phase 3 1

Therapeutic Areas

Pediatric Lymphoma 1
DIPG 1
Pediatric Brain Tumor 1
Waldenstrom Macroglobulinemia 1
Pediatric Solid Tumor 1
Small Lymphocytic Lymphoma 1
Lymphoplasmacytic Lymphoma 1
Marginal Zone Lymphoma 1
Rhabdomyosarcoma 1
Osteosarcoma 1

What is open in the Cellectar Biosciences pipeline

1 recruiting of 10 indexed (10% open); 5 completed (50%).

Phase mix: 1 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Pediatric Lymphoma (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Cellectar Biosciences: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Cellectar Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Cellectar BiosciencesAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Cellectar Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cellectar Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cellectar Biosciences page

10 registered trials is a research-attention snapshot, not an endorsement of Cellectar Biosciences or any single study.

  • 1 of Cellectar Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Pediatric Lymphoma is the condition Cellectar Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pediatric Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cellectar Biosciences pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.